Oncologic Drugs Committee Split on Risk-Benefit Profile of Pfizer Candidate

Drug Industry Daily
A A
An FDA advisory committee deadlocked 6 to 6 on whether the benefits of a Pfizer drug treatment for recurrent renal cell carcinoma outweighed the risks.

To View This Article:

Login

Subscribe To Drug Industry Daily